Currently, Sage Therapeutics Inc [SAGE] is trading at $14.18, up 3.58%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SAGE shares have gain 10.01% over the last week, with a monthly amount drifted -24.33%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Sage Therapeutics Inc [NASDAQ: SAGE] stock has seen the most recent analyst activity on April 17, 2024, when BofA Securities downgraded its rating to a Underperform and also revised its price target to $14 from $24. Previously, Deutsche Bank started tracking the stock with Hold rating on December 12, 2023, and set its price target to $21. On August 08, 2023, downgrade downgraded it’s rating to Hold. Goldman downgraded its rating to a Neutral but stick to its price target of $22 on August 08, 2023. Canaccord Genuity downgraded its rating to a Hold and reduced its price target to $21 on August 08, 2023. Wedbush downgraded its rating to Neutral for this stock on August 07, 2023, and downed its price target to $22. In a note dated August 07, 2023, Stifel downgraded an Hold rating on this stock and revised its target price from $60 to $22.
This stock has fluctuated between a low of $10.92 and a high of $59.99 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $49.69 within the next 12 months. Sage Therapeutics Inc [NASDAQ: SAGE] shares were valued at $14.18 at the most recent close of the market. An investor can expect a potential return of 250.42% based on the average SAGE price forecast.
Analyzing the SAGE fundamentals
Trailing Twelve Months sales for Sage Therapeutics Inc [NASDAQ:SAGE] were 91.06M which represents 139.89% growth. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -5.95%, Pretax Profit Margin comes in at -5.53%, and Net Profit Margin reading is -5.53%. To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is -0.61 and Total Capital is -0.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.64 points at the first support level, and at 13.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.72, and for the 2nd resistance point, it is at 15.25.
Sage Therapeutics Inc [SAGE] reported earnings per share of -$1.8 for its fiscal quarter that ended on 3/31/2024. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.65/share, meaning a difference of -$0.15 and a surprise factor of -9.10%. By comparison, the stated earnings for the previous quarter ended on 12/31/2023 were -$0.55 per share as compared to estimates of -$1.28 per share, a difference of $0.73 representing a surprise of 57.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Sage Therapeutics Inc [NASDAQ:SAGE] is 12.22. Also, the Quick Ratio is 12.22, while the Cash Ratio stands at 2.82. Considering the valuation of this stock, the price to sales ratio is 9.37, the price to book ratio is 1.21.
Transactions by insiders
Recent insider trading involved Barrett Elizabeth, Director, that happened on Aug 09 ’23 when 2000.0 shares were purchased. Director, Barrett Elizabeth completed a deal on May 09 ’23 to buy 1000.0 shares.
